InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-22.8%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by King Rachel K., Director. Director active across 2 companies, notably NOVAVAX INC. In total, 13 filings have been logged. Breakdown: 2 buys · 1 sell. Total volume traded: €196k. History available since 19 May 2021. The latest transaction was disclosed on 13 December 2024 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations13 total
4,150 shares@ US$9.020518.2% of flowCommon StockSEC:0001593968-25-000011:0
6,670 shares0Common StockSEC:0001593968-24-000862:0
3,334 shares@ US$3.0033.4% of flowCommon StockSEC:0001415889-24-009743:0
4,238 shares@ US$2.3632.5% of flowCommon stockSEC:0001209191-24-000068:0
6,667 shares@ US$1.5034.1% of flowCommon stockSEC:0001209191-23-051390:0
3,100 sharesCommon StockSEC:0001209191-23-036748:0
700 sharesCommon StockSEC:0001209191-22-038593:0
3,450 sharesCommon StockSEC:0001209191-21-052810:0
3,450 sharesCommon StockSEC:0001209191-21-052810
6,900 sharesCommon StockSEC:0001209191-21-043702
6,900 sharesCommon StockSEC:0001209191-21-043702:0
700 shares@ US$139.6450.0% of flowCommon StockSEC:0001209191-21-035008
Ideal exit: 13 Feb 2022 (T+270)
700 shares@ US$139.640.0054% mcap50.0% of flowCommon StockSEC:0001209191-21-035008:0
Ideal exit: 13 Feb 2022 (T+270)
13 of 13 declarations
About King Rachel K.
Rachel K. King is a Board Member at Novavax Inc. She plays a key role in the governance of the company, contributing to the definition of its strategy and guiding its research efforts. Her experience in the biopharmaceutical sector is valuable in guiding Novavax in its vaccine development initiatives.
